AstraZeneca’s Etcamah approved in the US for HR+ breast cancer
AstraZeneca PLC said Etcamah in combination with a CDK4/6 inhibitor has been approved in the US for 1st-line advanced HR-positive breast cancer. Approval is based on SERENA-6 Phase III trial results.
RNS Number: 5602T AstraZeneca PLC 07 September 2026 07 September 2026Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancerApproval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progres…